Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders of nervous system. The company's technology platform includes a catheter-based system incorporating microchip-enabled sensing architecture designed to detect low-amplitude neural signals from within the vascular system. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.…
Autonomix Highlights Renal Denervation Strategy and Vision for Illuminating the Nervous System at TCT 2026
Autonomix Medical (NASDAQ: AMIX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector.
The shares were at 0.8911 USD on 20 November 2026, down 94.7% over 52 weeks. Its 52-week range is 0.8800 USD to 32.55 USD: the price is 97.3% below the high and 1.3% above the low.
Its market capitalisation is 1.82M USD.
Autonomix Medical reports return on equity of -283.5% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 7.69M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.